Premature aging/senescence in cancer cells facing therapy: good or bad?
Normal and cancer cells facing their demise following exposure to radio-chemotherapy can actively participate in choosing their subsequent fate. These programmed cell fate decisions include true cell death (apoptosis-necroptosis) and therapy-induced cellular senescence (TIS), a permanent "proliferative arrest" commonly portrayed as premature cellular aging. Despite a permanent loss of proliferative potential, senescent cells remain viable and are highly bioactive at the microenvironment level, resulting in a prolonged impact on tissue architecture and functions. Cellular senescence is primarily documented as a tumor suppression mechanism that prevents cellular transformation. In the context of normal tissues, cellular senescence also plays important roles in tissue repair, but contributes to age-associated tissue dysfunction when senescent cells accumulate. Theoretically, in multi-step cancer progression models, cancer cells have already bypassed cellular senescence during their immortalization step (see hallmarks of cancer). It is then perhaps surprising to find that cancer cells often retain the ability to undergo TIS, or premature aging. This occurs because cellular senescence results from multiple signalling pathways, some retained in cancer cells, aiming to prevent cell cycle progression in damaged cells. Since senescent cancer cells persist after therapy and secrete an array of cytokines and growth factors that can modulate the tumor microenvironment, these cells may have beneficial and detrimental effects regarding immune modulation and survival of remaining proliferation-competent cancer cells. Similarly, while normal cells undergoing senescence are believed to remain indefinitely growth arrested, whether this is true for senescent cancer cells remains unclear, raising the possibility that these cells may represent a reservoir for cancer recurrence after treatment. This review discusses our current knowledge on cancer cell senescence and highlight questions that must be addressed to fully understand the beneficial and detrimental impacts of cellular senescence during cancer therapy.
CRCHUM et Institut du cancer de Montréal, Montreal, QC, Canada.
Llilians Calvo
LC
Gonzalez
CRCHUM et Institut du cancer de Montréal, Montreal, QC, Canada.
Sabrina
S
Ghadaouia
CRCHUM et Institut du cancer de Montréal, Montreal, QC, Canada.
Aurélie
A
Martinez
CRCHUM et Institut du cancer de Montréal, Montreal, QC, Canada. rodierf@mac.com.|Département de radiologie, radio-oncologie et médecine nucléaire, Université de Montréal, Montreal, QC, Canada. rodierf@mac.com.|CRCHUM Tour Viger R10-420, 900 St-Denis, Montreal, QC, H2X 0A9, Canada. rodierf@mac.com.
Francis
F
Rodier
D000375:Aging / Q000473:pathology*; D017209:Apoptosis; D016922:Cellular Senescence; D059248:Chemoradiotherapy / Q000379:methods*; D006801:Humans; D008954:Models, Biological; D009369:Neoplasms / Q000473:pathology* / Q000503:physiopathology / Q000628:therapy*; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
Aging; Apoptosis; Cancer cell fates; Cancer cell senescence; Cancer therapy; Cell death